STOCK TITAN

[Form 4] TNF Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Joshua Silverman, Executive Chairman and Director, reported the immediate grant and vesting of 8,644 Restricted Stock Units (RSUs) on 10/03/2025 for Q/C Technologies, Inc. (QCLS). The RSUs carried a reported price of $0 and vested immediately upon grant, increasing his total beneficial ownership to 8,673 shares following the transaction. The filing was signed on 10/06/2025 and was filed as a single-person Form 4. The entry indicates a non-derivative equity grant that vests on the grant date, which typically aligns executive incentives with shareholder value without an immediate cash outlay by the reporting person.

Joshua Silverman, Presidente Esecutivo e Amministratore, ha riferito la concessione immediata e la maturazione di 8.644 Restricted Stock Units (RSU) il 10/03/2025 per Q/C Technologies, Inc. (QCLS). Le RSU avevano un prezzo riportato di $0 e sono maturate immediatamente al momento della concessione, aumentando la sua proprietà beneficiaria totale a 8.673 azioni dopo la transazione. Il deposito è stato firmato il 10/06/2025 ed è stato presentato come un modulo Form 4 per una sola persona. L’annotazione indica un’assegnazione azionaria non derivativa che matura alla data di concessione, il che in genere allinea gli incentivi degli dirigenti al valore per gli azionisti senza un immediato esborso di cassa da parte della persona che segnala.

Joshua Silverman, Presidente Ejecutivo y Director, informó la concesión inmediata y la consolidación de 8,644 Restricted Stock Units (RSUs) el 10/03/2025 para Q/C Technologies, Inc. (QCLS). Las RSU tenían un precio reportado de $0 y se consolidaron de inmediato al otorgarse, aumentando su propiedad beneficiaria total a 8,673 acciones tras la transacción. El registro fue firmado el 10/06/2025 y se presentó como un Formulario 4 para una sola persona. La entrada indica una concesión de acciones no derivativas que se consolida en la fecha de otorgamiento, lo que normalmente alinea los incentivos de los ejecutivos con el valor para los accionistas sin un desembolso de efectivo inmediato por la persona que reporta.

Joshua Silverman, 최고경영책임자 겸 이사, 10/03/2025Q/C Technologies, Inc. (QCLS)를 위한 8,644개의 제한 주식 단위(RSUs)를 즉시 부여 및 vesting했다고 보고했다. RSU의 공시 가격은 $0였고 부여 시 즉시 vesting되어 거래 후 총 유익한 소유 주식 수가 8,673주로 증가했다. 서류는 10/06/2025에 서명되었고 단일인 Form 4로 filing되었다. 이 항목은 부여일에 vesting되는 비파생형 주식 보상을 나타내며, 이는 일반적으로 경영진의 인센티브를 주주가치와 일치시키고 보고자에 의한 즉시 현금 지출 없이 수행된다.

Joshua Silverman, Président Exécutif et Administrateur, a signalé l’octroi et l’acquisition immédiats de 8 644 Restricted Stock Units (RSU) le 10/03/2025 pour Q/C Technologies, Inc. (QCLS). Les RSU avaient un prix déclaré de $0 et ont acquis immédiatement leur droit à titre lors de l’octroi, portant la propriété bénéficiaire totale à 8 673 actions après la transaction. Le dépôt a été signé le 10/06/2025 et déposé sous forme de Formulaire 4 pour une seule personne. L’entrée indique une attribution d’actions non dérivative qui se vissent à la date d’octroi, ce qui aligne généralement les incitations des cadres avec la valeur pour les actionnaires sans déboursement de trésorerie immédiat par la personne déclarante.

Joshua Silverman, Executive Chairman und Director, berichtete über die sofortige Gewährung und Vesting von 8.644 Restricted Stock Units (RSUs) am 10/03/2025 für Q/C Technologies, Inc. (QCLS). Die RSUs hatten einen berichteten Preis von $0 und vesteten unmittelbar bei der Gewährung, wodurch sich sein Gesamtanteil am wirtschaftlich berechtigten Eigentum nach der Transaktion auf 8.673 Aktien erhöhte. Die Einreichung wurde am 10/06/2025 unterzeichnet und als Form 4 für eine Einzelperson eingereicht. Der Eintrag deutet auf eine nicht-derivative Aktienzuteilung hin, die am Gewährungsdatum vestet und typischerweise die Anreize der Führungskräfte mit dem Aktionärswert in Einklang bringt, ohne dass der Meldende unmittelbar Bargeld aufwenden muss.

جوشوا سيلفرمان، رئيس مجلس الإدارة التنفيذي والمدير، أبلغ عن المنحة الفورية ونمو RSUs لـ 8,644 وحدة أسهم مقيدة (RSUs) في 10/03/2025 لشركة Q/C Technologies, Inc. (QCLS). كانت RSU تحمل سعرًا مُبلغًا عنه وهو $0 وتملّكت فور المنح، مما زاد من ملكيته المفيدة الإجمالية إلى 8,673 سهمًا بعد الصفقة. تم توقيع الملف في 10/06/2025 وتقديمه كـ Form 4 لشخص واحد. يشير الإدخال إلى منح أسهم غير مشتقة تتملّك في تاريخ المنح، وهو ما يعادل عادة حوافز المدراء مع قيمة المساهمين دون تخصيص نقدي فوري من قبل الشخص المبلغ عنه.

Joshua Silverman,执行董事长及董事,报告于 10/03/2025Q/C Technologies, Inc. (QCLS) 授予并即时归属 8,644 份受限股票单位(RSUs)。RSU 的披露价格为 $0,在授予时立即归属,此次交易后其总受益所有权增至 8,673 股。该 filings 于 10/06/2025 签署,并以单人 Form 4 提交。该条目表示一种在授予日即归属的非派生性股权授予,通常使高管激励与股东价值保持一致,而不需要报告方立即现金支出。

Positive
  • None.
Negative
  • None.

Insights

Immediate vesting of RSUs raises alignment and disclosure clarity.

The grant of 8,644 RSUs that vested immediately on 10/03/2025 increases the Executive Chairman's direct stake to 8,673 shares, signaling a near-term alignment of his interests with other shareholders through additional equity ownership.

Immediate vesting reduces future service-based retention effects and concentrates value transfer to the grant date; investors may monitor subsequent grants or retention mechanisms for longer-term incentive alignment over the next 12 months.

Joshua Silverman, Presidente Esecutivo e Amministratore, ha riferito la concessione immediata e la maturazione di 8.644 Restricted Stock Units (RSU) il 10/03/2025 per Q/C Technologies, Inc. (QCLS). Le RSU avevano un prezzo riportato di $0 e sono maturate immediatamente al momento della concessione, aumentando la sua proprietà beneficiaria totale a 8.673 azioni dopo la transazione. Il deposito è stato firmato il 10/06/2025 ed è stato presentato come un modulo Form 4 per una sola persona. L’annotazione indica un’assegnazione azionaria non derivativa che matura alla data di concessione, il che in genere allinea gli incentivi degli dirigenti al valore per gli azionisti senza un immediato esborso di cassa da parte della persona che segnala.

Joshua Silverman, Presidente Ejecutivo y Director, informó la concesión inmediata y la consolidación de 8,644 Restricted Stock Units (RSUs) el 10/03/2025 para Q/C Technologies, Inc. (QCLS). Las RSU tenían un precio reportado de $0 y se consolidaron de inmediato al otorgarse, aumentando su propiedad beneficiaria total a 8,673 acciones tras la transacción. El registro fue firmado el 10/06/2025 y se presentó como un Formulario 4 para una sola persona. La entrada indica una concesión de acciones no derivativas que se consolida en la fecha de otorgamiento, lo que normalmente alinea los incentivos de los ejecutivos con el valor para los accionistas sin un desembolso de efectivo inmediato por la persona que reporta.

Joshua Silverman, 최고경영책임자 겸 이사, 10/03/2025Q/C Technologies, Inc. (QCLS)를 위한 8,644개의 제한 주식 단위(RSUs)를 즉시 부여 및 vesting했다고 보고했다. RSU의 공시 가격은 $0였고 부여 시 즉시 vesting되어 거래 후 총 유익한 소유 주식 수가 8,673주로 증가했다. 서류는 10/06/2025에 서명되었고 단일인 Form 4로 filing되었다. 이 항목은 부여일에 vesting되는 비파생형 주식 보상을 나타내며, 이는 일반적으로 경영진의 인센티브를 주주가치와 일치시키고 보고자에 의한 즉시 현금 지출 없이 수행된다.

Joshua Silverman, Président Exécutif et Administrateur, a signalé l’octroi et l’acquisition immédiats de 8 644 Restricted Stock Units (RSU) le 10/03/2025 pour Q/C Technologies, Inc. (QCLS). Les RSU avaient un prix déclaré de $0 et ont acquis immédiatement leur droit à titre lors de l’octroi, portant la propriété bénéficiaire totale à 8 673 actions après la transaction. Le dépôt a été signé le 10/06/2025 et déposé sous forme de Formulaire 4 pour une seule personne. L’entrée indique une attribution d’actions non dérivative qui se vissent à la date d’octroi, ce qui aligne généralement les incitations des cadres avec la valeur pour les actionnaires sans déboursement de trésorerie immédiat par la personne déclarante.

Joshua Silverman, Executive Chairman und Director, berichtete über die sofortige Gewährung und Vesting von 8.644 Restricted Stock Units (RSUs) am 10/03/2025 für Q/C Technologies, Inc. (QCLS). Die RSUs hatten einen berichteten Preis von $0 und vesteten unmittelbar bei der Gewährung, wodurch sich sein Gesamtanteil am wirtschaftlich berechtigten Eigentum nach der Transaktion auf 8.673 Aktien erhöhte. Die Einreichung wurde am 10/06/2025 unterzeichnet und als Form 4 für eine Einzelperson eingereicht. Der Eintrag deutet auf eine nicht-derivative Aktienzuteilung hin, die am Gewährungsdatum vestet und typischerweise die Anreize der Führungskräfte mit dem Aktionärswert in Einklang bringt, ohne dass der Meldende unmittelbar Bargeld aufwenden muss.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Silverman Joshua

(Last) (First) (Middle)
1185 AVENUE OF THE AMERICAS, SUITE 249

(Street)
NEW YORK NY 10036

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Q/C TECHNOLOGIES, INC. [ QCLS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Executive Chairman
3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 10/03/2025 A 8,644 A $0(1) 8,673 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents a grant of Restricted Stock Units ("RSUs"). The RSUs vested immediately upon grant on October 3, 2025.
/s/ Joshua Silverman 10/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
TNF Pharmaceuticals

NASDAQ:TNFA

TNFA Rankings

TNFA Latest News

TNFA Latest SEC Filings

TNFA Stock Data

9.60M
1.85M
0.01%
0.3%
3.21%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
NEW YORK